EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pre-operative risk assessment of hepatocellular carcinoma recurrence in liver transplant recipients by non-invasive detection of pre-existing genetic lesions

Suqin Yang, Sunbin Ling, Jianhua Li, Yan Wang, Jiapei Wang, Qiwei Huang, Fanming Liu, Yiqi Zhuang, Yingyu Zheng, Rui Wang, Zhe Yang, Xiaoping Zheng und 22 weitere

Clinical and Molecular Hepatology · 01.04.2026 · 32 (2) · 884-903

DOI: 10.3350/cmh.2025.1069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2026. Verfasst von Suqin Yang und 33 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Liver transplantation (LT) following total hepatectomy is a life-saving treatment for hepatocellular carcinoma (HCC). The HCC recurrence after LT hinders the effectiveness of the procedure. The objective of this study is to develop a pre-operative risk stratification model based on a liquid biopsy.

Methods

We conducted a comprehensive multi-omics study of 260 HCC patients from three centers, including clinical data, low-coverage whole-genome sequencing of cell-free DNA (cfDNA) from plasma, as well as whole-exome, single-nucleus RNA, and spatial transcriptomics from matched tumor and non-tumor tissues.

Results

We identified cfDNA-derived copy number alteration (CNA) signatures associated with post-transplant recurrence. By integrating cfDNA-derived CNA profiles with single-cell transcriptomic data, we traced recurrence-associated cfDNA to a distinct subpopulation of malignant cells within the primary tumor. These cells were embedded in a pro-metastatic microenvironment of specialized endothelial subtypes and cancer-associated fibroblasts. Notably, most recurrence-associated lesions were detectable in cfDNA prior to liver transplantation (LT). Building on these insights, we developed the ZJU Criteria based on CNA fragments and tumor markers, a pre-LT risk prediction tool that integrates conventional clinical factors with cfDNA-derived CNA signatures, and validated it using internal and independent external cohorts.

Conclusion

Our findings suggest that post-transplant recurrence commonly originates from advanced subclones that emerge late during tumor evolution. The ZJU Criteria provides an accurate, non-invasive strategy that significantly improves pre-LT risk stratification and clinical decision-making for patients with HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansLiver TransplantationFemaleDNA Copy Number VariationsMaleRisk AssessmentNeoplasm Recurrence, LocalMiddle AgedCell-Free Nucleic AcidsBiomarkers, TumorLiquid BiopsyTranscriptomeAged

Stichwörter der Autor:innen

Cell-free DNAHepatocellular carcinomaLiquid biopsyLiver transplantationMulti-omics

Substanzen

Cell-Free Nucleic AcidsBiomarkers, Tumor

Autor:innen und Institutionen

  • Zhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China, China.
  • General Surgery, Cancer Center, Department of Hepatobiliary and Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou…
  • Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Liver Transplantation Center, Department of General Surgery, Huashan Hospital & Institute of Organ Transplantation, Fudan University, Shanghai, China.
  • Department of Hepatobiliary and Pancreatic Surgery, NHC Key Laboratory of Combined Multi-Organ Transplantation, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • State Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, College of Life Science, Wuhan University, Wuhan, China.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Yang, S., Ling, S., Li, J., Wang, Y., Wang, J., Huang, Q., Liu, F., Zhuang, Y., Zheng, Y., Wang, R., Yang, Z., Zheng, X., Wang, K., Liu, Z., Chen, J., Wang, J., Xie, H., Zhou, L., Chen, L., …, & Xu, X. (2026). Pre-operative risk assessment of hepatocellular carcinoma recurrence in liver transplant recipients by non-invasive detection of pre-existing genetic lesions. Clinical and Molecular Hepatology, 32(2), 884-903. https://doi.org/10.3350/cmh.2025.1069

Vancouver

Yang S, Ling S, Li J, Wang Y, Wang J, Huang Q, et al. Pre-operative risk assessment of hepatocellular carcinoma recurrence in liver transplant recipients by non-invasive detection of pre-existing genetic lesions. Clinical and Molecular Hepatology. 2026;32(2):884-903. doi:10.3350/cmh.2025.1069

BibTeX
@article{Yang2026,
  author = {Yang, Suqin and Ling, Sunbin and Li, Jianhua and Wang, Yan and Wang, Jiapei and Huang, Qiwei and Liu, Fanming and Zhuang, Yiqi and Zheng, Yingyu and Wang, Rui and Yang, Zhe and Zheng, Xiaoping and Wang, Kai and Liu, Zhikun and Chen, Jun and Wang, Jianguo and Xie, Haiyang and Zhou, Lin and Chen, Leiming and Cao, Guoqiang and Chen, Dandan and Ji, Junfang and Zhao, Bin and Jiang, Chao and Lu, Di and Wei, Xuyong and Jiang, Hangjin and Shan, Qiaonan and Shi, Hengbo and Xu, Yong-Zhen and Zheng, Shusen and Wang, Zhengxin and Lin, Shengda and Xu, Xiao},
  title = {Pre-operative risk assessment of hepatocellular carcinoma recurrence in liver transplant recipients by non-invasive detection of pre-existing genetic lesions},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {2},
  pages = {884--903},
  doi = {10.3350/cmh.2025.1069}
}
Kostenlos starten →